These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

358 related items for PubMed ID: 19756413

  • 1. Rational approaches for drug designing against leishmaniasis.
    Shukla AK, Singh BK, Patra S, Dubey VK.
    Appl Biochem Biotechnol; 2010 Apr; 160(8):2208-18. PubMed ID: 19756413
    [Abstract] [Full Text] [Related]

  • 2. Glycobiology of the Leishmania parasite and emerging targets for antileishmanial drug discovery.
    Chandra S, Ruhela D, Deb A, Vishwakarma RA.
    Expert Opin Ther Targets; 2010 Jul; 14(7):739-57. PubMed ID: 20536412
    [Abstract] [Full Text] [Related]

  • 3. Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives.
    Croft SL, Engel J.
    Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S4-8. PubMed ID: 16904717
    [Abstract] [Full Text] [Related]

  • 4. [Canine leishmaniasis: evolution of the chemotherapeutic protocols].
    Oliva G, Foglia Manzillo V, Pagano A.
    Parassitologia; 2004 Jun; 46(1-2):231-4. PubMed ID: 15305724
    [Abstract] [Full Text] [Related]

  • 5. Current approaches to discover marine antileishmanial natural products.
    Tempone AG, Martins de Oliveira C, Berlinck RG.
    Planta Med; 2011 Apr; 77(6):572-85. PubMed ID: 21243582
    [Abstract] [Full Text] [Related]

  • 6. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H, Namba K.
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [Abstract] [Full Text] [Related]

  • 7. Antimicrobial peptides for leishmaniasis.
    Cobb SL, Denny PW.
    Curr Opin Investig Drugs; 2010 Aug; 11(8):868-75. PubMed ID: 20721829
    [Abstract] [Full Text] [Related]

  • 8. Kahalalide F, an antitumor depsipeptide in clinical trials, and its analogues as effective antileishmanial agents.
    Cruz LJ, Luque-Ortega JR, Rivas L, Albericio F.
    Mol Pharm; 2009 Aug; 6(3):813-24. PubMed ID: 19317431
    [Abstract] [Full Text] [Related]

  • 9. Synthesis and biological evaluation of trifluralin analogues as antileishmanial agents.
    Esteves MA, Fragiadaki I, Lopes R, Scoulica E, Cruz ME.
    Bioorg Med Chem; 2010 Jan 01; 18(1):274-81. PubMed ID: 19926293
    [Abstract] [Full Text] [Related]

  • 10. Current scenario of drug development for leishmaniasis.
    Croft SL, Seifert K, Yardley V.
    Indian J Med Res; 2006 Mar 01; 123(3):399-410. PubMed ID: 16778319
    [Abstract] [Full Text] [Related]

  • 11. New antileishmanial candidates and lead compounds.
    Richard JV, Werbovetz KA.
    Curr Opin Chem Biol; 2010 Aug 01; 14(4):447-55. PubMed ID: 20400358
    [Abstract] [Full Text] [Related]

  • 12. Complementary medicinal chemistry-driven strategies toward new antitrypanosomal and antileishmanial lead drug candidates.
    Cavalli A, Lizzi F, Bongarzone S, Belluti F, Piazzi L, Bolognesi ML.
    FEMS Immunol Med Microbiol; 2010 Feb 01; 58(1):51-60. PubMed ID: 19845762
    [Abstract] [Full Text] [Related]

  • 13. Leishmaniasis: drugs in the clinic, resistance and new developments.
    Ouellette M, Drummelsmith J, Papadopoulou B.
    Drug Resist Updat; 2004 Feb 01; 7(4-5):257-66. PubMed ID: 15533763
    [Abstract] [Full Text] [Related]

  • 14. Chemotherapy in the treatment and control of leishmaniasis.
    Alvar J, Croft S, Olliaro P.
    Adv Parasitol; 2006 Feb 01; 61():223-74. PubMed ID: 16735166
    [Abstract] [Full Text] [Related]

  • 15. Promising therapeutic targets for antileishmanial drugs.
    Werbovetz KA.
    Expert Opin Ther Targets; 2002 Aug 01; 6(4):407-22. PubMed ID: 12223057
    [Abstract] [Full Text] [Related]

  • 16. Recent advances in antileishmanial drug development.
    Davis AJ, Kedzierski L.
    Curr Opin Investig Drugs; 2005 Feb 01; 6(2):163-9. PubMed ID: 15751739
    [Abstract] [Full Text] [Related]

  • 17. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
    Sangraula H, Sharma KK, Rijal S, Dwivedi S, Koirala S.
    J Assoc Physicians India; 2003 Jul 01; 51():686-90. PubMed ID: 14621038
    [Abstract] [Full Text] [Related]

  • 18. [Interpretation of laboratory data during cryptic leishmaniasis in dog].
    Gravino AE.
    Parassitologia; 2004 Jun 01; 46(1-2):227-9. PubMed ID: 15305723
    [Abstract] [Full Text] [Related]

  • 19. Auranofin is an apoptosis-simulating agent with in vitro and in vivo anti-leishmanial activity.
    Sharlow ER, Leimgruber S, Murray S, Lira A, Sciotti RJ, Hickman M, Hudson T, Leed S, Caridha D, Barrios AM, Close D, Grögl M, Lazo JS.
    ACS Chem Biol; 2014 Mar 21; 9(3):663-72. PubMed ID: 24328400
    [Abstract] [Full Text] [Related]

  • 20. Protease inhibitors in potential drug development for Leishmaniasis.
    Das P, Alam MN, Paik D, Karmakar K, De T, Chakraborti T.
    Indian J Biochem Biophys; 2013 Oct 21; 50(5):363-76. PubMed ID: 24772958
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.